Lorcaserin
Antiobesity drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Lorcaserin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Lorcaserin, marketed under the brand name Belviq,[3][4] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite.[5] It was approved in 2012, and in 2020, it was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.[6][1]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Belviq |
Other names | APD-356 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613014 |
License data |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 70%[2] |
Metabolism | Hepatic (extensive)[2] |
Elimination half-life | 11 hours[2] |
Excretion | Renal (92.3%), Faecal (2.2%)[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.237.138 |
Chemical and physical data | |
Formula | C11H14ClN |
Molar mass | 195.69 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close